Case 1 – Maintenance treatment with trabectedin in advanced soft tissue sarcomas: when should we consider progression?

Abstract

We present the case of a patient with a locally advanced synovial sarcoma treated with neoadjuvant chemotherapy and subsequent surgery who presented an early metastatic relapse, wherein a rapid and significant response was achieved with trabectedin, and in whom maintenance of the drug until clinical progression of the disease allowed 27 cycles of treatment to be administered despite the patient presenting radiological progression according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria 15 cycles earlier.